MacIntyre N R
Respiratory Care Services, Duke University Medical Center, PO Box 3111, Durham, NC 27710, USA.
Respir Care. 2001 Nov;46(11):1294-303.
In long-term management of stable chronic obstructive pulmonary disease (COPD), a number of medications improve pulmonary function test results. The long-term clinical benefits of those drugs would seem intuitive, but there is very little strong evidence that long-term outcomes in COPD are substantially affected by those drugs. Nevertheless, symptom improvement such as dyspnea reduction is certainly strong reason to use those agents. The 2 most compelling bodies of evidence in stable COPD are for oxygen therapy in the chronically hypoxemic patient and pulmonary rehabilitation to improve exercise tolerance and dyspnea. Inhaled corticosteroids also appear to be useful in patients at risk for frequent exacerbations. In acute exacerbations, the rationale for therapy comes in part from the large body of literature regarding acute asthma therapy. Bronchodilator therapy and corticosteroids both seem to reduce the severity and the duration of exacerbations. Moreover, routine antibiotic use seems beneficial, and the role of noninvasive positive-pressure ventilation with patients suffering impending respiratory failure from acute COPD exacerbations is well supported by the literature.
在稳定期慢性阻塞性肺疾病(COPD)的长期管理中,多种药物可改善肺功能测试结果。这些药物的长期临床益处似乎是显而易见的,但几乎没有确凿证据表明这些药物会对COPD的长期预后产生实质性影响。然而,诸如减轻呼吸困难等症状改善无疑是使用这些药物的有力理由。稳定期COPD最有说服力的两方面证据是针对慢性低氧血症患者的氧疗以及改善运动耐量和呼吸困难的肺康复治疗。吸入性糖皮质激素似乎对有频繁急性加重风险的患者也有用。在急性加重期,治疗的理论依据部分来自大量关于急性哮喘治疗的文献。支气管扩张剂治疗和糖皮质激素似乎都能减轻急性加重的严重程度并缩短其持续时间。此外,常规使用抗生素似乎有益,并且无创正压通气在因急性COPD加重而即将发生呼吸衰竭的患者中的作用也得到了文献的充分支持。